quantum-computing

Amgen Sees RS Rating Improve To 71

INVESTOR'S BUSINESS DAILY

2 min read

0 likes

⚡ Quantum Brief

Amgen’s Relative Strength Rating climbed from 66 to 71 on December 2025, signaling improved price performance over the past 52 weeks. The IBD metric ranks stocks from 1 (worst) to 99 (best). The upgrade reflects Amgen’s growing market leadership amid a volatile sector, though medical stocks overall maintain modest relative strength. Analysts note solid entry points despite broader market chop. The rating evaluates stock performance against peers, with higher scores indicating stronger momentum. Amgen’s rise suggests investor confidence in its long-term growth potential. A brief unrelated mention warns quantum computing could disrupt cryptocurrency security, though no details were provided. This highlights emerging tech risks in financial markets. IBD’s analysis emphasizes timing for profit-taking, urging investors to monitor Relative Strength Ratings for strategic exits. The update aligns with broader market trends favoring biotech resilience.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

BREAKING: Stocks Open Higher; Tesla, Lilly Climb In Buy AreasIn a welcome move, Amgen (AMGN) saw its Relative Strength Rating improve from 66 to 71 on Monday.

When To Sell Stocks To Lock In Profits And Minimize Losses This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks…Despite low relative strength, medical stocks had solid entries in a choppy market. 11/21/2025 Despite low relative strength, medical stocks had solid entries in a choppy market. 11/21/2025 Despite low relative strength, medical stocks had solid entries in... In the wrong hands, quantum computing could undo cryptocurrency security features. (© Gary Neill)Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!Get market updates, educational videos, webinars, and stock analysis.Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.©2025 Investor’s Business Daily, LLC.

Read Original

Source Information

Source: Investor's Business Daily

Website: https://www.investors.com/feed/

Discussion

0 professional contributions

Be the first to add a constructive contribution.